Recently, several laboratories have described a generalized immunodeficiency syndrome in susceptible mouse strains following infection by a murine retrovirus isolate termed LP-BM5 (20, 24, 25) , that originated from the Duplan-Latarjet isolate (19) of murine leukemia virus (MuLV). The LP-BM5 isolate is a complex mixture of MuLV including ecotropic, mink cell focus-inducing, and defective viruses; currently it is generally agreed that the defective genome is the proximal agent causing the immunodeficiency (1, 3, 11, 15) . Although this murine immunodeficiency is not initiated by a lentivirus, the syndrome bears a number of characteristics similar to those of AIDS and has been termed murine AIDS (MAIDS). Among the similarities are severe immunodeficiency of both T-and B-cell responses, dependence of the initiation of disease on the presence of CD4+ T cells, hypergammaglobulinemia, lymphadenopathy, increased susceptibility to progressive infection by environmental pathogens that cause only inapparent infections without mortality in normal individuals (2, 12, 17, 18, 20, (24) (25) (26) (27) 35) , and an increased incidence of tumors, particularly terminal B-cell lineage lymphomas. As has been suggested for cytotoxic T-lymphocyte (CTL) responses to human immunodeficiency virus (30, 31, 33, 34) , the development or, conversely, the lack of the generation of CTLs to LP-BM5 MuLV-infected cells might play a critical role in the initiation and maintenance of MAIDS. In the present study we address the question of whether the prototype MAIDSsusceptible C57BL/6 (B6) strain can generate CTLs specific to LP-BM5 MuLV-induced tumors and infected cells.
The B6-1710 and B6-1153 tumors, established as biologically cloned cell lines from lymphomas from infected B6 mice which had features of MAIDS, are of the B-cell lineage: B220+, CD5+, Lyb-8+, Ly-17+, ThB+ (17) , and Ia+ ( Fig. 1A and B) and (ii) an antigen(s) expressed on both B6-1153 and B6-1710 tumor cells at roughly similar functional levels (Fig. 1C) . This view was strongly supported by the results with additional target cells (Fig. 1) (5, 6, 13, 22, 23, 29) . Along these lines, it should be noted that the MHC seems to control the incidence of MAIDS (10, 21) ; specifically, the major determinant of genetic resistance or susceptibility to MAIDS in crosses between susceptible H-2b and resistant H-2d mice mapped to H-2D, and rather surprisingly, susceptibility was found to be a dominant trait (21) . These results are thus consistent with the possibility that class I MHCrestricted recognition of virus-infected cells by CD8+ CTLs is involved in disease pathogenesis. Alternatively, antiviral CTL responses might be viewed as helpful in protection from, or slowing of the progression of, the immunodeficiency if these responses could be enhanced before the immunodeficiency has become full-blown (see below). Flow cytometric analyses of viral antigen expression showed that only B6-1710 expressed gag-related specificities at readily detectable levels (Table 1) . Whether the presences on B6-1710 of both serologically defined gag-encoded products and a dominant CTL-defined epitope are related is uncertain. Because of the novel sequences defined for the p12-and p15-encoding regions of the gag gene of the defective virus (1, 3, 14) and our finding that LP-BM5-infected but not LP-BM5-derived ecotropic virus-infected spleen cells stimulate CTL responses to the MAIDS tumors (Table 4) , it is tempting to speculate, however, that the antiviral CTLs directed to the dominant CTL epitope preferentially expressed by B6-1710 may be specific for the defective gag product, which exists as a unique 60-kDa precursor. The observations that the B6-1153 tumor, although carrying integrated copies of the defective genome, Values of spontaneous release from the target cells were 15% for B6-1710 and 16% for B6-1153. B6 spleen cells that were used as stimulator cells were obtained from either age-matched normal mice or mice that had been infected with 0.4 ml of either the complete LP-BM5 virus complex or the biologically cloned ecotropic component of LP-BM5. The titers of infectious ecotropic virus in the two preparations, as measured by the X-C plaque test, were approximately equal, being within less than a factor of 2.
appears to express 1/10 as much mRNA related to the defective virus as does the B6-1710 tumor (Table 1) and expresses the novel 60-kDagag product in the cytoplasm but not on the cell surface (16) 
